Showing 1691-1700 of 2652 results for "".
- Increasing Surgery Volume Will Fuel Single-Use Ophthalmic Surgical Device Markethttps://modernod.com/news/increasing-surgery-volume-will-fuel-single-use-ophthalmic-surgical-device-market/2479784/According to Market Scope research, two factors will drive healthy growth in the single-use ophthalmic surgical product market over the next 5 years: an aging world population, which will lead to steady growth in ophthalmic surgeries, and rising concerns over cross-contamination. Market Sc
- Staar Surgical Announces Agreement with Dr. Tobias Neuhann in Germany to Create Collaboration with Single Site Ophthalmology Clinicshttps://modernod.com/news/staar-surgical-announces-agreement-with-dr-tobias-neuhann-in-germany-to-create-collaboration-with-single-site-ophthalmology-clinics/2479798/Staar Surgical announced a multi-year strategic alliance agreement with Tobias Neuhann, MD, of the Augenklinik am Marienplatz (Eye Clinic at Marienplatz) in Munich, Germany. The agreement serves as a global partnership model for smaller and single site refractive surgery eye clinics that aim to p
- Orbis Flying Eye Hospital Begins 2-Week Training Project to Improve Eye Care Across Rwandahttps://modernod.com/news/orbis-flying-eye-hospital-begins-two-week-training-project-to-improve-eye-care-across-rwanda/2482898/The Orbis Flying Eye Hospital landed in Kigali, Rwanda, on July 18, 2025, marking the beginning of a historic 2-week training project. It marks the first time this aircraft has visited Rwanda, where Orbis' teams of clinical staff and volunteer faculty will work alongside t
- Opthea Treats Final Patient in Phase 3 COAST Trial for Wet AMDhttps://modernod.com/news/opthea-treats-final-patient-in-phase-3-coast-trial-for-wet-amd/2482668/Opthea announced that it has completed the final week 52 patient visit in COAST, the first of two phase 3 pivotal trials investigating the superiority and safety of sozinibercept in combination with aflibercept (COAST) or ranibizumab (ShORe), compared to standard of care alone for the treatm
- AAO: Home OCT Device Improves Care for AMD Patients, Reduces Costs and Burdenhttps://modernod.com/news/aao-home-oct-device-improves-care-for-amd-patients-reduces-costs-and-burden/2482499/A newly approved home-based OCT device developed by Notel Vision is allowing patients to monitor their own eye health between appointments, providing physicians with crucial data without requiring in-office visits, according to an AAO news release. A study presented today at AAO 2024 suggest
- Alcon to Showcase Latest Innovations at AAO 2024 Annual Meetinghttps://modernod.com/news/alcon-to-showcase-latest-innovations-at-aao-2024-annual-meeting/2482489/Alcon will unveil its latest clinical data and product innovations at the American Academy of Ophthalmology (AAO) 2024 annual meeting. Attendees, including ophthalmologists, surgical staff, researchers, and industry leaders, are invited to visit Alcon at booth #4008 for hands-on demonstrations an
- Oculis Begins Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-begins-phase-3-optimize-2-trial-of-ocs-01-for-the-treatment-of-inflammation-and-pain-following-cataract-surgery/2482022/Oculis Holding announced 'First Patient First Visit' (FPFV) in the OCS-01 phase 3 OPTIMIZE-2 trial for the treatment of inflammation and pain following cataract surgery. Data from the phase 3 OPTIMIZE-2 trial is intended to support the company’s NDA submission to the FDA. If ap
- Oculis Commences Stage 2 of Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in DMEhttps://modernod.com/news/oculis-announces-first-patient-first-visit-in-phase-3-diamond-1-trial-of-ocs-01-eye-drop-in-dme/2482015/Oculis Holding announced that the 'First Patient First Visit (FPFV)' in stage 2 of its phase 3 DIAMOND-1 trial evaluating OCS-01 for the treatment of DME. DIAMOND-1 is a phase 3, two-stage, double-masked, randomized, multicenter trial to assess the efficacy and sa
- Visus Therapeutics Completes Enrollment in BRIO-I Phase 3 Trial of Brimochol PF for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-completes-enrollment-in-brio-i-a-phase-3-clinical-trial-of-brimochol-pf-for-the-treatment-of-presbyopia/2481483/Visus Therapeutics announced it has completed patient enrollment and the last visit had been conducted in BRIO-I, a phase 3 trial for its lead asset, Brimochol PF, a preservative-free topical ophthalmic solution for the treatment of presbyopia. “We are thrilled to have reache
- AI Can Identify Heart Disease From an Eye Scanhttps://modernod.com/news/ai-can-identify-heart-disease-from-an-eye-scan/2480602/Scientists have developed an artificial intelligence system that can analyze eye scans taken during a routine visit to an optician or eye clinic and identify patients at a high risk of a heart attack, according to a University of Leeds, UK, news release. Doctors have recognized th